Corrias, G, Lai, E, Ziranu, P, Mariani, S, Donisi, C, Liscia, N, Saba, G, Pretta, A, Persano, M, Fanni, D, Spanu, D, Balconi, F, Loi, F, Deidda, S, Restivo, A, Pusceddu, V, Puzzoni, M, Solinas, C, Massa, E, Madeddu, C et al, Gerosa, C, Zorcolo, L, Faa, G, Saba, L and Scartozzi, M (2024) Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging. Cancers, 16 (7).

Preview

Text Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Colorectal cancer (CRC) is a leading tumor worldwide. In CRC, the angiogenic pathway plays a crucial role in cancer development and the process of metastasis. Thus, anti-angiogenic drugs represent a milestone for metastatic CRC (mCRC) treatment and lead to significant improvement of clinical outcomes. Nevertheless, not all patients respond to treatment and some develop resistance. Therefore, the identification of predictive factors able to predict response to angiogenesis pathway blockade is required in order to identify the best candidates to receive these agents. Unfortunately, no predictive biomarkers have been prospectively validated to date. Over the years, research has focused on biologic factors such as genetic polymorphisms, circulating biomarkers, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA. Moreover, research efforts have evaluated the potential correlation of molecular biomarkers with imaging techniques used for tumor assessment as well as the application of imaging tools in clinical practice. In addition to functional imaging, radiomics, a relatively newer technique, shows real promise in the setting of correlating molecular medicine to radiological phenotypes.

Item Type:	Article
Uncontrolled Keywords:	angiogenesis; anti-angiogenic treatment; biologic factors; metastatic colorectal cancer; prediction of response; radiomics; Cancer; Precision Medicine; Digestive Diseases; Genetics; Biomedical Imaging; Cancer Genomics; Colo-Rectal Cancer; Human Genome; Genetic Testing; Women's Health; 4.2 Evaluation of markers and technologies; 4.1 Discovery and preclinical testing of markers and technologies; Cancer; 3 Good Health and Well Being; 1112 Oncology and Carcinogenesis
Subjects:	Q Science > QH Natural history > QH301 Biology R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Biological and Environmental Sciences (from Sep 19)
Publisher:	MDPI
SWORD Depositor:	A Symplectic
Date Deposited:	29 Nov 2024 10:57
Last Modified:	29 Nov 2024 11:00
DOI or ID number:	10.3390/cancers16071364
URI:	https://researchonline.ljmu.ac.uk/id/eprint/24934

View Item